HMGCoA-reductase inhibitors in dementia

Benefit or harm

Kalpana P. Padala, Jane Frances Potter, Tsuneya Ikezu

Research output: Contribution to journalReview article

Abstract

Dementia is a syndrome characterized by a decline in cognitive function. Alzheimer's disease and cerebro-vascular disease are the most common causes of dementia. Many factors (genetic, life style, vascular etc.) appear to play some role in the development of dementia. Statins significantly reduce vascular disease and could reduce cognitive impairment in later life. Although most cross-sectional and longitudinal studies suggested a lower incidence of dementia in long-term statin users, randomized trials of statins in dementia did not slow disease progression. Furthermore, the effect of statins on cognitive performance is not well understood. Case reports suggest that statins may adversely affect cognition in some individuals, and prospective data studying the effects of statins in cognitively normal individuals is limited. Thus, the effects of statins on cognition in late life, remains uncertain.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalClinical Medicine: Geriatrics
Volume2009
Issue number3
StatePublished - Dec 1 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dementia
Oxidoreductases
Cognition
Vascular Diseases
Blood Vessels
Longitudinal Studies
Disease Progression
Life Style
Alzheimer Disease
Cross-Sectional Studies
Incidence

Keywords

  • Cholesterol
  • Cognition
  • Dementia
  • Statins
  • Vascular risk factors

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

HMGCoA-reductase inhibitors in dementia : Benefit or harm. / Padala, Kalpana P.; Potter, Jane Frances; Ikezu, Tsuneya.

In: Clinical Medicine: Geriatrics, Vol. 2009, No. 3, 01.12.2009, p. 13-22.

Research output: Contribution to journalReview article

Padala, Kalpana P. ; Potter, Jane Frances ; Ikezu, Tsuneya. / HMGCoA-reductase inhibitors in dementia : Benefit or harm. In: Clinical Medicine: Geriatrics. 2009 ; Vol. 2009, No. 3. pp. 13-22.
@article{63693f12a0e24be0a12d13ab2b58b1f6,
title = "HMGCoA-reductase inhibitors in dementia: Benefit or harm",
abstract = "Dementia is a syndrome characterized by a decline in cognitive function. Alzheimer's disease and cerebro-vascular disease are the most common causes of dementia. Many factors (genetic, life style, vascular etc.) appear to play some role in the development of dementia. Statins significantly reduce vascular disease and could reduce cognitive impairment in later life. Although most cross-sectional and longitudinal studies suggested a lower incidence of dementia in long-term statin users, randomized trials of statins in dementia did not slow disease progression. Furthermore, the effect of statins on cognitive performance is not well understood. Case reports suggest that statins may adversely affect cognition in some individuals, and prospective data studying the effects of statins in cognitively normal individuals is limited. Thus, the effects of statins on cognition in late life, remains uncertain.",
keywords = "Cholesterol, Cognition, Dementia, Statins, Vascular risk factors",
author = "Padala, {Kalpana P.} and Potter, {Jane Frances} and Tsuneya Ikezu",
year = "2009",
month = "12",
day = "1",
language = "English (US)",
volume = "2009",
pages = "13--22",
journal = "Clinical Medicine: Geriatrics",
issn = "1178-217X",
number = "3",

}

TY - JOUR

T1 - HMGCoA-reductase inhibitors in dementia

T2 - Benefit or harm

AU - Padala, Kalpana P.

AU - Potter, Jane Frances

AU - Ikezu, Tsuneya

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Dementia is a syndrome characterized by a decline in cognitive function. Alzheimer's disease and cerebro-vascular disease are the most common causes of dementia. Many factors (genetic, life style, vascular etc.) appear to play some role in the development of dementia. Statins significantly reduce vascular disease and could reduce cognitive impairment in later life. Although most cross-sectional and longitudinal studies suggested a lower incidence of dementia in long-term statin users, randomized trials of statins in dementia did not slow disease progression. Furthermore, the effect of statins on cognitive performance is not well understood. Case reports suggest that statins may adversely affect cognition in some individuals, and prospective data studying the effects of statins in cognitively normal individuals is limited. Thus, the effects of statins on cognition in late life, remains uncertain.

AB - Dementia is a syndrome characterized by a decline in cognitive function. Alzheimer's disease and cerebro-vascular disease are the most common causes of dementia. Many factors (genetic, life style, vascular etc.) appear to play some role in the development of dementia. Statins significantly reduce vascular disease and could reduce cognitive impairment in later life. Although most cross-sectional and longitudinal studies suggested a lower incidence of dementia in long-term statin users, randomized trials of statins in dementia did not slow disease progression. Furthermore, the effect of statins on cognitive performance is not well understood. Case reports suggest that statins may adversely affect cognition in some individuals, and prospective data studying the effects of statins in cognitively normal individuals is limited. Thus, the effects of statins on cognition in late life, remains uncertain.

KW - Cholesterol

KW - Cognition

KW - Dementia

KW - Statins

KW - Vascular risk factors

UR - http://www.scopus.com/inward/record.url?scp=75749124277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749124277&partnerID=8YFLogxK

M3 - Review article

VL - 2009

SP - 13

EP - 22

JO - Clinical Medicine: Geriatrics

JF - Clinical Medicine: Geriatrics

SN - 1178-217X

IS - 3

ER -